Current understanding and management of giant cell arteritis and polymyalgia rheumatica

References

• Machado EB, Michet CJ, Ballard DJ et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950–1985. Arthritis Rheum.31, 745–749 (1988).
   PubMed Web of Science ®Google Scholar
• Salvarani C, Gabriel SE, O’Fallon WM, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970–1991. Arthritis Rheum.38, 369–373 (1995).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore)86, 61–68 (2007).
   PubMed Web of Science ®Google Scholar
• González-Gay MA, García-Porrúa C, Vázquez-Caruncho M, Dababneh A, Hajeer A, Ollier WE. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J. Rheumatol.26, 1326–1332 (1999).
   PubMed Web of Science ®Google Scholar
• Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001. Ann. Rheum. Dis.65, 1093–1098 (2006).
   PubMed Web of Science ®Google Scholar
• Blockmans D, de Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum.55, 131–137 (2006).
   PubMed Web of Science ®Google Scholar
• Robbin and Cotran Pathologic Basis of Disease. Kumar VA, Abbas AK, Fausto N (Eds). Elsevier Saunders, PA, USA (2005).
   Google Scholar
• Salvarani C, Cantini F, Olivieri I, Hunder GS. Polymyalgia rheumatica: a disorder of extraarticular synovial structures? J. Rheumatol.26, 517–521 (1999).
   PubMed Web of Science ®Google Scholar
• Meliconi R, Pulsatelli L, Uguccioni M et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum.39, 1199–1207 (1996).
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin. Arthritis Rheum.33, 38–48 (2003).
   PubMed Web of Science ®Google Scholar
• Salvarani C, Boiardi L, Mantovani V et al. HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. Ann. Rheum. Dis.58, 303–308 (1999).
   PubMed Web of Science ®Google Scholar
• Hernández-Rodríguez J, García-Martínez A, Casademont J et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum.47, 29–35 (2002).
   PubMed Web of Science ®Google Scholar
• Mattey DL, Hajeer AH, Dababneh A et al. Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms. Arthritis Rheum.43, 1749–1755 (2000).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Hajeer AH, Dababneh A et al. IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin. Exp. Rheumatol.20, 179–184 (2002).
   PubMed Web of Science ®Google Scholar
• Makki RF, al Sharif F, González-Gay MA, García-Porrúa C, Ollier WE, Hajeer AH. RANTES gene polymorphism in polymyalgia rheumatica, giant cell arteritis and rheumatoid arthritis. Clin. Exp. Rheumatol.18, 391–393 (2000).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Hajeer AH, Dababneh A et al. Corticotropin releasing hormone promoter polymorphisms in giant cell arteritis and polymyalgia rheumatica. Clin. Exp. Rheumatol.20, 133–138 (2002).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Hajeer AH, Dababneh A et al. Interferon-γ gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica. Clin. Exp. Rheumatol.22, S18–S20 (2004).
   PubMed Web of Science ®Google Scholar
• Rueda B, Lopez-Nevot MA, Lopez-Diaz MJ, Garcia-Porrua C, Martín J, Gonzalez-Gay MA. A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. J. Rheumatol.32, 1737–1741 (2005).
   PubMed Web of Science ®Google Scholar
• Segarra M, García-Martínez A, Sánchez M et al. Gelatinase expression and proteolytic activity in giant-cell arteritis. Ann. Rheum. Dis.66, 1429–1435 (2007).
   PubMed Web of Science ®Google Scholar
• Rueda B, Miranda-Filloy JA, Martin J, Gonzalez-Gay MA. Association of CD24 gene polymorphisms with susceptibility to biopsy-proven giant cell arteritis. J. Rheumatol.35, 850–854 (2008).
   PubMed Web of Science ®Google Scholar
• Salvarani C, Gabriel SE, O’Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann. Intern. Med.123, 192–194 (1995).
   PubMed Web of Science ®Google Scholar
• Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J. Rheumatol.23, 112–119 (1996).
   PubMed Web of Science ®Google Scholar
• Narvaez J, Clavaguera MT, Nolla-Sole JM, Valverde-Garcia J, Roig-Escofet D. Lack of association between infection and onset of polymyalgia rheumatica. J. Rheumatol.27, 953–957 (2000).
   PubMed Web of Science ®Google Scholar
• Wagner AD, Gérard HC, Fresemann T et al. Detection of Chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells. Arthritis Rheum.43, 1543–1551 (2000).
   PubMedGoogle Scholar
• López-Hoyos M, Alvarez L, Ruiz Soto M, Blanco R, José Bartolomé M, Martínez-Taboada VM. Serum levels of antibodies to Chlamydia pneumoniae and human HSP60 in giant cell arteritis patients. Clin. Exp. Rheumatol.26, 1107–1110 (2008).
   PubMed Web of Science ®Google Scholar
• Brack A, Geisler A, Martinez-Taboada VM, Younge BR, Goronzy JJ, Weyand CM. Giant cell vasculitis is a T cell-dependent disease. Mol. Med.3, 530–543 (1997).
   PubMed Web of Science ®Google Scholar
• Weyand CM, Schönberger J, Oppitz U, Hunder NN, Hicok KC, Goronzy JJ. Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J. Exp. Med.179, 951–960 (1994).
   PubMed Web of Science ®Google Scholar
• Ma -Krupa W, Jeon MS, Spoerl S, Tedder TF, Goronzy JJ, Weyand CM. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J. Exp. Med.199, 173–183 (2004).
   PubMed Web of Science ®Google Scholar
• Oriss TB, Ostroukhova M, Seguin-Devaux C et al. Dynamics of dendritic cell phenotype and interactions with CD4+ T cells in airway inflammation and tolerance. J. Immunol.174, 854–863 (2005).
   PubMed Web of Science ®Google Scholar
• Lau AH, Thomson AW. Dendritic cells and immune regulation in the liver. Gut52, 307–314 (2003).
   PubMed Web of Science ®Google Scholar
• Pryshchep O, Ma-Krupa W, Younge BR, Goronzy JJ, Weyand CM. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation118, 1276–1284 (2008).
   PubMed Web of Science ®Google Scholar
• Otero C, Eisele PS, Schaeuble K, Groettrup M, Legler DF. Distinct motifs in the chemokine receptor CCR7 regulate signal transduction, receptor trafficking and chemotaxis. J. Cell. Sci.121, 2759–2767 (2008).
   PubMed Web of Science ®Google Scholar
• Krupa WM, Dewan M, Jeon MS et al. Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis. Am. J. Pathol.161, 1815–1823 (2002).
   PubMed Web of Science ®Google Scholar
• Cid MC, Hoffman MP, Hernández-Rodríguez J et al. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis. Rheumatology (Oxford)45, 1356–1363 (2006).
   PubMed Web of Science ®Google Scholar
• Martinez-Taboada VM, Alvarez L, RuizSoto M, Marin-Vidalled MJ, Lopez-Hoyos M. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine44, 207–220 (2008).
   PubMed Web of Science ®Google Scholar
• Cutolo M, Straub RH, Foppiani L et al. Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6. J. Rheumatol.29, 748–756 (2002).
   PubMed Web of Science ®Google Scholar
• Ross R. Cellular and molecular studies of atherogenesis. Atherosclerosis131(Suppl.), S3–S4 (1997).
   PubMed Web of Science ®Google Scholar
• Salvarani C, Macchioni PL, Tartoni PL et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin. Exp. Rheumatol.5, 205–215 (1987).
   PubMed Web of Science ®Google Scholar
• Makkuni D, Bharadwaj A, Wolfe K, Payne S, Hutchings A, Dasgupta B. Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? Rheumatology (Oxford)47, 488–490 (2008).
   PubMed Web of Science ®Google Scholar
• Pulsatelli L, Dolzani P, Silvestri T et al. Synovial expression of vasoactive intestinal peptide in polymyalgia rheumatica. Clin. Exp. Rheumatol.24, 562–566 (2006).
   PubMed Web of Science ®Google Scholar
• Emilie D, Liozon E, Crevon MC et al. Production of interleukin 6 by granulomas of giant cell arteritis. Hum. Immunol.39, 17–24 (1994).
   PubMed Web of Science ®Google Scholar
• Lecron JC, Roblot P, Chevalier S et al. High circulating leukaemia inhibitory factor (LIF) in patients with giant cell arteritis: independent regulation of LIF and IL-6 under corticosteroid therapy. Clin. Exp. Immunol.92, 23–26 (1993).
   PubMed Web of Science ®Google Scholar
• Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum.36, 1286–1294 (1993).
   PubMed Web of Science ®Google Scholar
• Uddhammar A, Sundqvist KG, Ellis B, Rantapaa-Dahlqvist S. Cytokines and adhesion molecules in patients with polymyalgia rheumatica. Br. J. Rheumatol.37, 766–769 (1998).
   PubMedGoogle Scholar
• Roblot P, Morel F, Lelievre E, Gascan H, Wijdenes J, Lecron JC. Serum cytokine and cytokine receptor levels in patients with giant cell arteritis during corticotherapy. J. Rheumatol.23, 408–410 (1996).
   PubMed Web of Science ®Google Scholar
• Straub RH, Herfarth HH, Rinkes B et al. Favorable role of interleukin 10 in patients with polymyalgia rheumatica. J. Rheumatol.26, 1318–1325 (1999).
   PubMed Web of Science ®Google Scholar
• Cutolo M, Montecucco CM, Cavagna L et al. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann. Rheum. Dis.65, 1438–1443 (2006).
   PubMed Web of Science ®Google Scholar
• Corrigall VM, Dolan AL, Dasgupta B, Panayi GS. The sequential analysis of T lymphocyte subsets and interleukin-6 in polymyalgia rheumatica patients as predictors of disease remission and steroid withdrawal. Br. J. Rheumatol.36, 976–980 (1997).
   PubMedGoogle Scholar
• Hernandez-Rodriguez J, Segarra M, Vilardell C et al. Tissue production of pro-inflammatory cytokines (IL-1β, TNF-α and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford)43, 294–301 (2004).
   PubMed Web of Science ®Google Scholar
• Hernandez-Rodriguez J, Segarra M, Vilardell C et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation107, 2428–2434 (2003).
   PubMed Web of Science ®Google Scholar
• Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum.43, 1041–1048 (2000).
   PubMed Web of Science ®Google Scholar
• Weyand CM, Wagner AD, Bjornsson J, Goronzy JJ. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J. Clin. Invest.98, 1642–1649 (1996).
   PubMed Web of Science ®Google Scholar
• Hunder GG, Bloch DA, Michel BA et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum.33, 1122–1128 (1990).
   PubMed Web of Science ®Google Scholar
• Brooks RC, McGee SR. Diagnostic dilemmas in polymyalgia rheumatica. Arch. Intern. Med.157, 162–168 (1997).
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Olivieri I, Hunder GG. The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J. Rheumatol.27, 2179–2184 (2000).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Olivieri I, Hunder GG. Polymyalgia manifestations in different conditions mimicking polymyalgia rheumatica. Clin. Exp. Rheumatol.18, 755–759 (2000).
   PubMed Web of Science ®Google Scholar
• Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann. Rheum. Dis.38, 434–439 (1979).
   PubMed Web of Science ®Google Scholar
• Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann. Intern. Med.97, 672–680 (1982).
   PubMed Web of Science ®Google Scholar
• Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann. Rheum. Dis.40, 1–5 (1981).
   PubMed Web of Science ®Google Scholar
• Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin. Arthritis Rheum.13, 322–328 (1984).
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Salvarani C, Schirmer M et al. Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J. Rheumatol.35, 270–277 (2008).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore)84, 269–276 (2005).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Amor-Dorado JC, Llorca J. Fever in biopsy-proven giant cell arteritis: clinical implications in a defined population. Arthritis Rheum.51, 652–655 (2004).
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Amor-Dorado JC, Llorca, J. Giant cell arteritis without clinically evident vascular involvement in a defined population. Arthritis Rheum.51, 274–277 (2004).
   PubMedGoogle Scholar
• González-Gay MA, García-Porrúa C, Llorca J et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore)79, 283–292 (2000).
   PubMed Web of Science ®Google Scholar
• Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum.48, 3522–3531 (2003).
   PubMed Web of Science ®Google Scholar
• Penn H, Dasgupta B. Giant cell arteritis. Autoimmun. Rev.2, 199–203 (2003).
   PubMed Web of Science ®Google Scholar
• Franzen P, Sutinen S, von Knorring J. Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984–1988. J. Rheumatol.19, 273–276 (1992).
   PubMed Web of Science ®Google Scholar
• Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA287, 92–101 (2002).
   PubMed Web of Science ®Google Scholar
• Schmidt WA, Kraft HE, Vorpahl K, Volker L, Gromnica-Ihle EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. N. Engl. J. Med.337, 1336–1342 (1997).
   PubMed Web of Science ®Google Scholar
• Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JP. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann. Intern. Med.142, 359–369 (2005).
   PubMed Web of Science ®Google Scholar
• Blockmans D, Coudyzer W, Vanderschueren S et al. Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology (Oxford)47, 1179–1184 (2008).
   PubMed Web of Science ®Google Scholar
• Bley TA, Uhl M, Carew J et al. Diagnostic value of high-resolution MR imaging in giant cell arteritis. AJNR Am. J. Neuroradiol.28, 1722–1727 (2007).
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Hutchings A, Matteson EL. Polymyalgia rheumatica: the mess we are now in and what we need to do about it. Arthritis Rheum.55, 518–520 (2006).
   PubMed Web of Science ®Google Scholar
• Bahlas S, Ramos-Remus C, Davis P. Utilisation and costs of investigations, and accuracy of diagnosis of polymyalgia rheumatica by family physicians. Clin. Rheumatol.19, 278–280 (2000).
   PubMed Web of Science ®Google Scholar
• Frediani B, Falsetti P, Storri L et al. Evidence for synovitis in active polymyalgia rheumatica: sonographic study in a large series of patients. J. Rheumatol.29, 123–130 (2002).
   PubMed Web of Science ®Google Scholar
• McGonagle D, Pease C, Marzo-Ortega H et al. Comparison of extracapsular changes by magnetic resonance imaging in patients with rheumatoid arthritis and polymyalgia rheumatica. J. Rheumatol.28, 1837–1841 (2001).
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Nannini C et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin. Exp. Rheumatol.23, 462–468 (2005).
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Olivieri I et al. Proximal bursitis in active polymyalgia rheumatica. Ann. Int. Med.127, 27–31 (1997).
   PubMed Web of Science ®Google Scholar
• Lange U, Piegsa M, Teichmann J, Neeck G. Ultrasonography of the glenohumeral joints – a helpful instrument in differentiation in elderly onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatol. Int.19, 185–189 (2000).
   PubMed Web of Science ®Google Scholar
• Cantini F, Salvarani C, Olivieri I et al. Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate. Arthritis Rheum.44, 1155–1159 (2001).
   PubMed Web of Science ®Google Scholar
• Salvarani C, Barozzi L, Cantini F et al. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann. Rheum. Dis.67, 758–761 (2008).
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Borg FA, Hassan N et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford)49, 1594–1597 (2010).
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Borg FA, Hassan N et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford)49, 186–190 (2010).
   PubMed Web of Science ®Google Scholar
• Loddenkemper T, Sharma P, Katzan I, Plant GT. Risk factors for early visual deterioration in temporal arteritis. J. Neurol. Neurosurg. Psychiatry78, 1255–1259 (2007).
   PubMed Web of Science ®Google Scholar
• Tarkkanen A. Giant cell arteritis and the ophthalmologist. Acta Ophthalmol. Scand.80, 353–354 (2002).
   PubMedGoogle Scholar
• Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology110, 1204–1215 (2003).
   PubMed Web of Science ®Google Scholar
• Proven A, Gabriel SE, Orces C, O’Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum.49, 703–708 (2003).
   PubMed Web of Science ®Google Scholar
• Mazlumzadeh M, Hunder GG, Easley KA et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum.54, 3310–3318 (2006).
   PubMed Web of Science ®Google Scholar
• Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum.46, 457–466 (2002).
   PubMedGoogle Scholar
• Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum.50, 1332–1337 (2004).
   PubMed Web of Science ®Google Scholar
• Narváez J, Bernad B, Gómez-Vaquero C et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin. Exp. Rheumatol.26, S57–S62 (2008).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Piñeiro A, Gomez-Gigirey A et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore)83, 342–347 (2004).
   PubMed Web of Science ®Google Scholar
• Berger CT, Wolbers M, Meyer P, Daikeler T, Hess C. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology (Oxford)48, 258–261 (2009).
   PubMed Web of Science ®Google Scholar
• Salvarani C, Della Bella C, Cimino L et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford)48, 250–253 (2009).
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Rendt-Zagar KE et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann. Intern. Med.146, 621–630 (2007).
   PubMed Web of Science ®Google Scholar
• Mahr AD, Jova JA, Spiera RF et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum.56, 2789–2797 (2007).
   PubMed Web of Science ®Google Scholar
• De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann. Rheum. Dis.45, 136–138 (1986).
   PubMed Web of Science ®Google Scholar
• Dharmapaliah C, Borg F, Dasgupta B. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Rheumatology (Oxford)48, i42 (2009).
   Google Scholar
• Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum.44, 2933–2935 (2001).
   PubMed Web of Science ®Google Scholar
• Bhatia A, Ell PJ, Edwards JC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann. Rheum. Dis.64, 1099–1100 (2005).
   PubMed Web of Science ®Google Scholar
• Mayrbaeurl B, Hinterreiter M, Burgstaller S, Windpessl M, Thaler J. The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab. Clin. Rheumatol.26, 1597–1598 (2007).
   PubMed Web of Science ®Google Scholar
• Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann. Rheum. Dis.67, 625–630 (2008).
   PubMed Web of Science ®Google Scholar
• Catoggio W, Soriano ER, Imamura PM. Treatment of polymyalgia rheumatica: lower initial dose. Br. J. Rheumatol.30, 393–395 (1991).
   PubMedGoogle Scholar
• Kremers HM, Reinalda MS, Crowson CS et al. Relapse in a population based cohort of patients with polymyalgia rheumatica. J. Rheumatol.32, 65–73 (2005).
   PubMed Web of Science ®Google Scholar
• Caporali R, Cimmino MA, Ferraccioli G et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med.141, 493–500 (2004).
   PubMed Web of Science ®Google Scholar
• Salvarani C, Macchioni P, Manzini C et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann. Intern. Med.146, 631–639 (2007).
   PubMed Web of Science ®Google Scholar
• Catanoso MG, Macchioni P, Boiardi L, Pipitone N, Salvarani C. Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Arthritis Rheum.57, 1514–1519 (2007).
   PubMed Web of Science ®Google Scholar
• Warrington KJ, Jarpa EP, Crowson CS et al. Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study. Arthritis Res. Ther.11, R50 (2009).
   PubMedGoogle Scholar